Adlai Nortye Ltd. (ANL)
Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 20265 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Adlai Nortye Ltd.’s names, not what it holds today.
14 published
3 published
| Granted | Patent | Title | Field | Owner as printed |
|---|---|---|---|---|
| Jul 22, 2025 | 12,364,702 | Highly active sting protein agonist compound | Pharmaceuticals | ADLAI NORTYE BIOPHARMA CO., LTD. |
| Sep 17, 2024 | 12,091,398 | PD-L1 antagonist compound | Organic fine chemistry | ADLAI NORTYE BIOPHARMA CO., LTD. |
| Apr 23, 2024 | 11,965,875 | System and method for screening and assessing agents for tumor immunotherapy | Analysis of biological materials | ADLAI NORTYE BIOPHARMA CO., LTD. |
| Jun 20, 2023 | 11,680,271 | Construction of fully human antibody yeast display technique | Organic fine chemistry | ADLAI NORTYE BIOPHARMA CO., LTD. |
| Sep 7, 2021 | 11,111,230 | Indoleamine 2,3-dioxygenase inhibitors and use of same in medicine | Organic fine chemistry | ADLAI NORTYE BIOPHARMA CO., LTD. |
| Published | Application | Title | Field | Owner as printed |
|---|---|---|---|---|
| Dec 18, 2025 | 2025/0381143 | A SOLID PHARMACEUTICAL COMPOSITION | Pharmaceuticals | ADLAI NORTYE BIOPHARMA CO., LTD. |
| Jul 17, 2025 | 2025/0230245 | A FUSION POLYPEPTIDE AND ITS USE | Biotechnology | ADLAI NORTYE BIOPHARMA CO., LTD. |
| May 22, 2025 | 2025/0163062 | WNT PATHWAY INHIBITOR COMPOUNDS | Organic fine chemistry | ADLAI NORTYE BIOPHARMA CO., LTD. |
| Nov 7, 2024 | 2024/0368147 | CYCLIN K DEGRADER | Organic fine chemistry | ADLAI NORTYE BIOPHARMA CO., LTD. |
| Aug 29, 2024 | 2024/0287093 | HIGH ACTIVITY STING PROTEIN AGONIST | Pharmaceuticals | ADLAI NORTYE BIOPHARMA CO., LTD. |
| Aug 29, 2024 | 2024/0285640 | COMBINATION THERAPY FOR TREATING PIK3CA-MUTATED CANCER | Pharmaceuticals | ADLAI NORTYE BIOPHARMA CO., LTD. |
| Jun 13, 2024 | 2024/0189320 | HIGHLY ACTIVE STING PROTEIN AGONIST COMPOUND | Pharmaceuticals | ADLAI NORTYE BIOPHARMA CO., LTD. · patent 12,364,702 granted from it |
| Mar 14, 2024 | 2024/0085425 | BIOMARKER AND APPLICATION THEREOF | Analysis of biological materials | ADLAI NORTYE BIOPHARMA CO., LTD. |
| Feb 8, 2024 | 2024/0043551 | ANTI-TNFR2 ANTIBODY AND APPLICATION THEREOF | Organic fine chemistry | ADLAI NORTYE BIOPHARMA CO., LTD. |
| Dec 14, 2023 | 2023/0399327 | HIGH ACTIVITY HPK1 KINASE INHIBITOR | Organic fine chemistry | ADLAI NORTYE BIOPHARMA CO., LTD. |
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.